Company intelligence / Profile preview
Xeris Biopharma Holdings, Inc.
Chicago, Illinois, United Statesxerispharma.com ↗
- Ownership
- Public · XERS
- Development stage
- Commercial
01
Overview
Xeris has three FDA-approved products on the market: Gvoke® (ready-to-use liquid glucagon for severe hypoglycemia), Keveyis® (for primary periodic paralysis), and Recorlev® (for endogenous Cushing's syndrome). The company reported $164M in revenue for full year 2023, with Q4 2023 showing a 34% increase from the same period in the previous year[5]. Gvoke holds 34% of the retail glucagon market, and Recorlev has expanded its patient base by 124%[6].
- Therapeutic areas
- EndocrinologyNeurology
- Modalities
- Injectable drug formulationsready-to-use liquid formulations
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Amgen (for development of subcutaneous formulation of teprotumumab using XeriJect® technology)
04
Financials
- Market cap
- $2.4B
- Total revenue
- $291.8M
- Enterprise value
- $2.5B
Beyond the preview
Go deeper on Xeris Biopharma Holdings, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xeris Biopharma Holdings, Inc..